Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Carcinoma, Renal Cell · Human Immunodeficiency Virus (HIV) Infection

Merck KGaA, Darmstadt

Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt clinical programs — 63 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Frankfurter Str. 250, Darmstadt, 64293, DE HQ
7,364 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Frankfurter Str. 250, Darmstadt, 64293, DE
Employees
7,364
Programs
63
Drugs
50
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Merck KGaA, Darmstadt projects

63 ClinicalTrials.gov programs sponsored by Merck KGaA, Darmstadt.

Merck KGaA, Darmstadt has 63 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

63 programs

Clinical programs

Page 1 of 2

  1. Clesrovimab

    Merck KGaA, Darmstadt, Germany

    Respiratory Syncytial Virus Infection

    phase 3 mab completed

    1 trial

  2. DOR/ISL

    Merck KGaA, Darmstadt, Germany

    HIV Infection

    phase 3 small molecule active

    1 trial

  3. IV Tulisokibart

    Merck KGaA, Darmstadt, Germany

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  4. IV Tulisokibart

    Merck KGaA, Darmstadt, Germany

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  5. Lenvatinib

    Merck KGaA, Darmstadt, Germany

    Carcinoma, Hepatocellular

    phase 3 small molecule completed

    1 trial

  6. MK-8527

    Merck KGaA, Darmstadt, Germany

    Human Immunodeficiency Virus (HIV)

    phase 3 small molecule active

    1 trial

  7. Molnupiravir

    Merck KGaA, Darmstadt, Germany

    Coronavirus Disease (COVID-19)

    phase 3 small molecule active

    2 trials

  8. Nemtabrutinib

    Merck KGaA, Darmstadt, Germany

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  9. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Cervical Cancer

    phase 3 mab completed

    1 trial

  10. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Urinary Bladder Neoplasms

    phase 3 small molecule active

    1 trial

  11. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Triple Negative Breast Neoplasms

    phase 3 mab completed

    1 trial

  12. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Solid Tumors

    phase 3 small molecule active

    1 trial

  13. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Renal Cell Carcinoma

    phase 3 mab completed

    1 trial

  14. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Ovarian Cancer

    phase 3 mab completed

    1 trial

  15. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Metastatic Esophageal Squamous Cell Carcinoma

    phase 3 mab active

    1 trial

  16. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Gastric Neoplasms

    phase 3 mab completed

    1 trial

  17. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Endometrial Neoplasms

    phase 3 mab active

    1 trial

  18. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Carcinoma, Renal Cell

    phase 3 mab active

    1 trial

  19. Pembrolizumab (K)

    Merck KGaA, Darmstadt, Germany

    Breast Cancer

    phase 3 mab active

    1 trial

  20. Pembrolizumab/Vibostolimab

    Merck KGaA, Darmstadt, Germany

    Lung Neoplasms

    phase 3 mab completed

    1 trial

  21. Prevnar 13™

    Merck KGaA, Darmstadt, Germany

    Pneumococcal Infections

    phase 3 mab completed

    1 trial

  22. Recombinant human luteinizing hormone (r-hLH)

    Merck KGaA, Darmstadt, Germany

    Hypogonadism

    phase 3 small molecule completed

    1 trial

  23. Sacituzumab tirumotecan

    Merck KGaA, Darmstadt, Germany

    Breast Neoplasms

    phase 3 small molecule active

    1 trial

  24. Sacituzumab tirumotecan

    Merck KGaA, Darmstadt, Germany

    Non-small Cell Lung Cancer (NSCLC)

    phase 3 mab active

    2 trials

  25. Sacituzumab tirumotecan

    Merck KGaA, Darmstadt, Germany

    Non Small Cell Lung Cancer

    phase 3 mab active

    1 trial

  26. Teriflunomide

    Merck KGaA, Darmstadt, Germany

    Relapsing Multiple Sclerosis

    phase 3 small molecule terminated

    1 trial

  27. V114

    Merck KGaA, Darmstadt, Germany

    Pneumococcal Infections

    phase 3 mab completed

    1 trial

  28. V114

    Merck KGaA, Darmstadt, Germany

    Acute Otitis Media (AOM)

    phase 3 mab completed

    1 trial

  29. V181

    Merck KGaA, Darmstadt, Germany

    Healthy

    phase 3 mab active

    1 trial

  30. Vericiguat

    Merck KGaA, Darmstadt, Germany

    Chronic Heart Failure With Reduced Ejection Fraction

    phase 3 small molecule completed

    1 trial

  31. Zilovertamab vedotin

    Merck KGaA, Darmstadt, Germany

    Diffuse Large B-Cell Lymphoma

    phase 3 mab active

    1 trial

  32. cetuximab + cisplatin + vinorelbine

    Merck KGaA, Darmstadt, Germany

    Non Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule completed

    1 trial

  33. favezelimab/pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Colorectal Cancer

    phase 3 mab completed

    1 trial

  34. pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Non-small Cell Lung Cancer

    phase 3 mab completed

    2 trials

  35. pembrolizumab/vibostolimab

    Merck KGaA, Darmstadt, Germany

    Carcinoma, Non-Small-Cell Lung

    phase 3 mab active

    1 trial

  36. Belzutifan

    Merck KGaA, Darmstadt, Germany

    Carcinoma, Renal Cell

    phase 2 small molecule active

    1 trial

  37. Cetuximab

    Merck KGaA, Darmstadt, Germany

    Metastatic Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  38. DOR/ISL

    Merck KGaA, Darmstadt, Germany

    HIV-1 Infection

    phase 2 small molecule completed

    1 trial

  39. Daptomycin for Injection

    Merck KGaA, Darmstadt, Germany

    Bacteremia

    phase 2 small molecule completed

    1 trial

  40. Docetaxel

    Merck KGaA, Darmstadt, Germany

    Castration-Resistant Prostatic Cancer

    phase 2 small molecule active

    1 trial

  41. Doravirine

    Merck KGaA, Darmstadt, Germany

    Human Immunodeficiency Virus (HIV) Infection

    phase 2 small molecule active

    1 trial

  42. Efinopegdutide

    Merck KGaA, Darmstadt, Germany

    Non-alcoholic Fatty Liver Disease

    phase 2 small molecule completed

    1 trial

  43. Efinopegdutide 20 mg/mL

    Merck KGaA, Darmstadt, Germany

    Nonalcoholic Fatty Liver Disease

    phase 2 small molecule completed

    1 trial

  44. Intismeran autogene

    Merck KGaA, Darmstadt, Germany

    Malignant Melanoma

    phase 2 mab active

    1 trial

  45. M5049 low dose

    Merck KGaA, Darmstadt, Germany

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  46. MK-1167

    Merck KGaA, Darmstadt, Germany

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  47. MK-2214

    Merck KGaA, Darmstadt, Germany

    Early Alzheimer's Disease

    phase 2 mab active

    1 trial

  48. MK-6194

    Merck KGaA, Darmstadt, Germany

    Systemic Lupus Erythematosus

    phase 2 mab terminated

    1 trial

Frequently asked questions

How many clinical projects does Merck KGaA, Darmstadt have?

63 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.